Dilemmas in the compassionate supply of investigational cancer drugs

Internal Medicine Journal

Volumn 44, Issue 9, 2014, Pages 841-845

  Lewis, Jan R R ^a   Lipworth, W ^a,b   Kerridge, I ^a,c   Doran, E ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Ethics; Evidence based medicine; Health services accessibility; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE ACCESS; HEALTH PROGRAM; MEDICAL ETHICS; REIMBURSEMENT; AUSTRALIA; COMPASSIONATE USE; ETHICS; HEALTH CARE DELIVERY; HUMAN; MEDICAL RESEARCH; NEOPLASMS; PATIENT RIGHT; PATIENT SELECTION; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; AUSTRALIA; BIOMEDICAL RESEARCH; COMPASSIONATE USE TRIALS; DRUGS, INVESTIGATIONAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; PATIENT RIGHTS; PATIENT SELECTION;

EID: 84912120353     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12530     Document Type: Article

References (15)

1. Melanoma Skin Cancer [Internet]. American Cancer Society [cited 2014 Jul 30]. Available from URL: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507-16.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363: 711-23.
4. Azad A, Franco M. Co-funded expanded access programmes for new oncology drugs: creating a two-tier system for Australian cancer patients? Intern Med J 2013; 43: 843-4.
5. Furmansky L. Just say no to drugs: the Abigail Alliance and the attempted abolition of the food and drug administration. Biotechnol Law Report 2007; 26: 108-17.
6. Okie S. Access before approval-a right to take experimental drugs? New Engl J Med 2006; 355: 437-40.
7. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. New Engl J Med 2004; 351: 1707-9.
8. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962; 267: 1238-44 concl.
9. Annas GJ. Cancer and the constitution-choice at life's end. N Eng J Med 2007; 357: 408-13.
10. Négrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. Am Soc Clin Oncol 2000; 18: 4009-15.
11. Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 2012; 17: 229-39.
12. Sarin PS, Goldstein AL. Treatment of AIDS with drugs targeted to inhibit different stages of the HIV life cycle. Immunopharmacol Immunotoxicol 1995; 17: 217-45.
13. Amorosa V, Tebas P. Is it time to rethink the expanded-access programs for HIV infection? J Infect Dis 2007; 196: 974-7.
14. Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. Philos Public Aff1997; 26: 303-50.
15. Lewis JRR, Lipworth WL, Kerridge IH, Day RO. The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust 2013; 199: 471-3.